0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
Letters   |    
Arrhythmia and Antipsychotic Medications
Siow-Ann Chong, M.B.B.S.; Mythily, M.B.B.S., M.D.
Psychiatric Services 2001; doi: 10.1176/appi.ps.52.9.1257

To the Editor: In a review in the May issue of the cardiac effects of antipsychotic medications (1), among the risk factors for QT prolongation mentioned by Dr. Fayek and his colleagues was the inhibition of the cytochrome P-450 enzyme system by concomitant medications. Of these enzymes, CYP2D6 is particularly important, because a number of antipsychotic agents, including thioridazine, are its substrates.

Not only may the enzymes' activity be inhibited by other medications, but there is also genetic polymorphism for this enzyme, which confers different metabolizer status. Persons with normal rates of metabolism are classified as "extensive metabolizers," and those with lower rates are referred to as "poor metabolizers." In the case of CYP2D6, the proportion of poor metabolizers ranges from 5 to 10 percent among Caucasians, compared with less than 1 percent among Asians (2). Poor metabolizers not only are missing the hepatic component of CYP2D6-mediated metabolism but also lack right ventricular CYP2D6 expression (3). Thus compromised presystemic and target tissue metabolism of most antipsychotic medications in these patients may render them more vulnerable to the cardiotoxic effects of some of these drugs.

Extensive metabolizers who are Chinese tend to have slightly slower metabolic rates than Caucasian extensive metabolizers because of the presence of a special allele (4). Therefore these individuals may be more susceptible to the adverse effects of psychotropic drugs. The presence of this genetic vulnerability has led to the proposal of pharmacogenotyping patients before antipsychotic medications are prescribed (3).

In addition to the risk factors that Dr. Fayek and his associates have highlighted, the presence of stress and extremes of emotion or physical exertion, such as those associated with the use of restraints, may also predispose a patient to arrhythmia (5).

The authors are affiliated with the Institute of Mental Health and with Woodbridge Hospital in Singapore.

Fayek M, Kingsbury SJ, Zada J, et al: Cardiac effects of antipsychotic medications. Psychiatric Services 52:607-609,  2001
[PubMed]
[CrossRef]
 
Glue P, Banfield C: Psychiatry, psychopharmacology, and P-450s. Human Psychopharmacology 11:97-114,  1996
[CrossRef]
 
Idle RJ: The heart of psychotropic drug therapy [letter]. Lancet 355:1445,  2000
 
Yue QY, Svensson JO, Alm C, et al: Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. British Journal of Clinical Pharmacology 28:629-37,  1989
[PubMed]
 
Royal College of Psychiatrists: The Association Between Antipsychotic Drugs and Sudden Death. Council Report CR57. London, Royal College of Psychiatrists, 1997
 
+

References

Fayek M, Kingsbury SJ, Zada J, et al: Cardiac effects of antipsychotic medications. Psychiatric Services 52:607-609,  2001
[PubMed]
[CrossRef]
 
Glue P, Banfield C: Psychiatry, psychopharmacology, and P-450s. Human Psychopharmacology 11:97-114,  1996
[CrossRef]
 
Idle RJ: The heart of psychotropic drug therapy [letter]. Lancet 355:1445,  2000
 
Yue QY, Svensson JO, Alm C, et al: Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. British Journal of Clinical Pharmacology 28:629-37,  1989
[PubMed]
 
Royal College of Psychiatrists: The Association Between Antipsychotic Drugs and Sudden Death. Council Report CR57. London, Royal College of Psychiatrists, 1997
 
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 10.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 10.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 12.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 10.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 9.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles
Long-term efficacy and safety of iloperidone: an update. Neuropsychiatr Dis Treat 2014;10():409-15.